All In Biotech

Drug Trial Radar · NCT06056947

Evaluation of Efficacy and Safety of Two New Formulations Compared to Gynomax® XL Ovule

Phase III Study to Evaluate Efficacy and Safety of Different Formulations of Fenticonazole + Tinidazole + Lidocaine in the Treatment of Bacterial Vaginosis, Candidal Vulvovaginitis, Trichomonal Vaginitis and Mixed Infections

Last checked: Nov 19, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 577 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

577

Actual

Start

Jul 20, 2020

Primary completion

May 6, 2021

Study completion Aug 26, 2021

Sponsor

Lead sponsor
Ege UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Monitor CRO; Exeltis Turkey
First posted
Sep 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Efficacy and safety of two new formulations compared to Gynomax® XL ovule in the treatment of trichomonal vaginitis, bacterial vaginosis, candidal vulvovaginitis and mixed vaginal infections was evaluated in this randomized, three-arms, multicentral study.

Conditions

  • Trichomonal Vaginitis
  • Bacterial Vaginosis
  • Candidal Vulvovaginitis
  • Mixed Vaginal Infections

Interventions

  • EVEGYN ADrug

    EVEGYN A: Fixed-dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)

  • EVEGYN BDrug

    EVEGYN B: Fixed-dose combination of 600 mg fenticonazole nitrate + 2000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)

  • Gynomax® XL Vaginal OvuleDrug

    200 mg tioconazole + 300 mg tinidazole + 100 mg lidocaine single dose / day, during three consecutive days (1x1 / 3 days)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients who had complete response to treatment according to clinical findingsTime frame: 13 days (+/- 5 days) after treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ege University Family Planning and Infertility Application and Research Center

    Izmir, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.